Sec Form 4/A Filing - Sinclair Michael @ Lightlake Therapeutics Inc. - 2014-12-10

FORM 4/A Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Sinclair Michael 2. Issuer Name and Ticker or Trading Symbol Lightlake Therapeutics Inc. [ LLTP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner X __ Officer (give title below) _____ Other (specify below) Executive Chairman (Last) (First) (Middle) 445 PARK AVENUE, 9TH FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 12/10/2014 (Street) NEW YORK, NY10022 4. If Amendment, Date Original Filed (MM/DD/YY) 11/06/2015 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common stock, par value $0.001 per share ( 1 ) ( 2 ) ( 3 ) ( 4 ) 01/15/2015 S 1,700 A $ 3.5 144,070 D Common stock, par value $0.001 per share 01/16/2015 A 1,700 A $ 3.69 145,770 D Common stock, par value $0.001 per share 01/20/2015 A 1,600 A $ 3.69 147,370 D Common stock, par value $0.001 per share 01/21/2015 A 1,500 A $ 3.94 148,870 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s ) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Options ( 5 ) $ 8 05/01/2013( 6 ) A 130,000 05/01/2013( 6 ) 04/30/2023( 6 ) Common Stock, par value $0.001 per share 130,000 ( 7 ) 475,000 D Options $ 10 05/01/2013( 8 ) A 105,000 05/01/2013( 8 ) 04/30/2023( 8 ) Common Stock, par value $0.001 per share 105,000 ( 7 ) 580,000 D Options $ 15 08/01/2013 A 50,000 08/01/2013 07/31/2023 Common Stock, par value $0.001 per share 50,000 ( 7 ) 630,000 D Options $ 20 08/01/2013 A 50,000 08/01/2013 07/31/2023 Common Stock, par value $0.001 per share 50,000 ( 7 ) 680,000 D Options $ 6 12/31/2013 A 75,000 12/31/2013 12/30/2023 Common Stock, par value $0.001 per share 75,000 ( 7 ) 755,000 D Options $ 5 06/15/2014 A 150,000 06/15/2014( 9 ) 06/14/2024 Common Stock, par value $0.001 per share 150,000 ( 7 ) 905,000 D Options $ 8 06/15/2014 A 100,000 06/15/2014( 9 ) 06/14/2024 Common Stock, par value $0.001 per share 100,000 ( 7 ) 1,005,000 D Options $ 7.25 10/27/2015 A 250,000 10/27/2015( 10 ) 10/26/2025 Common Stock, par value $0.001 per share 250,000 ( 7 ) 1,255,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Sinclair Michael 445 PARK AVENUE, 9TH FLOOR NEW YORK, NY10022 X X Executive Chairman Signatures /s/ Michael Sinclair 12/03/2015 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The Reporting Person filed a Form 4 on November 6, 2015 (the "Original Form"). The Original Form is being amended (the "Form 4 Amendment") to correct the Original Form. This Form 4 Amendment discloses how many Table I securities (i.e., shares of common stock) the Reporting Person owned on May 31, 2012 (the date of the last voluntary Form 4 filed by the Reporting Person that disclosed transactions in shares of common stock) and January 14, 2015 (the day before the first transaction reported on this Form 4 Amendment). This Form 4 Amendment also corrects how many shares the Reporting Person now owns. Finally, this Form 4 Amendment deletes two entries from the Table I disclosure. ( 2 )This Form 4 Amendment reports the changes in beneficial ownership of the Reporting Person as of December 3, 2015. The Original Form 4 was required to be filed within two business days of 12/10/2014, the effective date of the Issuer's Form 8-A registration statement which registered the common stock of the Issuer for the first time under Section 12 of the Exchange Act. The Reporting Person voluntarily filed a Form 3 and a Form 4 on May 31, 2012 and voluntarily filed another Form 4 on January 25, 2013. In December 2014 , the Issuer effected a one-for-one hundred reverse stock split of its common stock (the "1:100 Reverse Stock Split"). Unless otherwise noted, all share amounts and exercise prices listed in this Form 4 Amendment have been retroactively adjusted for the 1:100 Reverse Stock Split as if such stock splits occurred prior to the issuance of such shares, warrants, or options. ( 3 )Footnote 2 continued - As of the May 31, 2012 Form 4 (the date of the last voluntary Form 4 filed by the Reporting Person that disclosed transactions in shares of common stock), the Reporting Person owned 50,820 shares of the Issuer's common stock: 23,820 shares directly; 15,000 shares owned indirectly through the Reporting Person's wife; and 12,000 shares owned indirectly through joint pension funds. During the period of May 31, 2012 through January 14, 2015: (a) the Reporting Person's wife transferred her 15,000 shares to the Reporting Person for no consideration; (b) the Reporting Person acquired 32,150 shares on unknown dates and at unknown prices; and (c) the Reporting Person's children transferred 60,000 shares to the Reporting Person for no consideration. ( 4 )Footnote 2 continued - Thus, for purposes of this Form 4 Amendment, the Reporting Person owned 142,370 shares prior to the first transaction reported on this Form 4 Amendment in the following manner: (x) 40,720 shares held in certificate form directly by the Reporting Person; (y) 19,650 shares held in certificate form indirectly by (i) Proton Therapy USA, a entity owned jointly by the Reporting Person and his son (5,000 shares); (ii) the first pension fund (10,000 shares); (iii) the second pension fund (2,000 shares); and (iv) Clearsearch Ltd., an entity who holds the shares for the benefit of the Reporting Person (2,650 shares); and (z) 82,000 shares held in electronic form for the benefit of the Reporting Person. ( 5 )As of the January 25, 2013 Form 4 (the date of the last voluntary Form 4 filed by the Reporting Person that disclosed transactions in derivate securities), the Reporting Person owned 345,000 derivative securities: 60,000 shares of common stock issuable upon exercise of stock options and 285,000 shares of common stock issuable upon the exercise of warrants. ( 6 )50,000 vested on 5/1/2013, 50,000 vested on 11/1/2013, and 30,000 vested on 12/31/2013. All expire 10 years after their respective vesting dates. ( 7 )Cashless Options. ( 8 )25,000 vested on 5/1/2013, 25,000 vested on 8/1/2013; 25,000 vested on 11/1/13, and 30,000 vested on 12/31/13. All expire 10 years after their respective vesting dates. ( 9 )These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of the next trial with respect to the opioid overdose reversal treatment; (B) the entrance into a distribution, licensing, royalty, partnership, collaboration, or other significant transaction with respect to the opioid overdose reversal treatment; or (C) the filing of a New Drug Application with the U.S. Food and Drug Administration with respect to the opioid overdose reversal treatment; and (ii) the Expiration Date. ( 10 )These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of three trials on or subsequent to October 23, 2015; or (B) (1) the approval by the U.S. Food and Drug Administration of the New Drug Application with respect to the opioid overdose reversal treatment; and (2) the commencement of two trials on or subsequent to October 23, 2015; and (ii) the Expiration Date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.